Volume 1, The Organic Chemistry of Drug Synthesis

Daniel Lednicer, PhD, is the author of several books on drug synthesis and discovery. His career in both the private and public sectors has been devoted to the search for new therapeutic agents. Dr. Lednicer spent two decades at the bench as a chemist at the Upjohn Company. Following that, he served as director of chemical research at Mead Johnson, director of pharmaceutical sciences at Adria Laboratories, and pharmaceutical manager at Analytical Biochemistry Laboratories. Most recently, he was a project officer at the National Cancer Institute.

Lester A. Mitscher, Ph.D., recognized for his research achievements by numerous institutions, serves as a consultant for the National Institutes of Health, among other organizations. Dr. Mitscher is a professor at the University of Kansas and the Victorian College of Pharmacy at Monash University outside Melbourne, Australia. Victoria Dolby Toews, MPH, a veteran freelance researcher and writer, has written and coauthored many books on health and wellness. She lives in the Pacific Northwest.

Updated every five years, the series represents the optimal compromise between currency and a sufficient body of material for cohesive and comprehensive treatment in a monograph. Provides a quick yet thorough overview of the synthetic routines that have been used to access specific classes of therapeutic agents. Materials are organized by chemical class, and syntheses are taken back to available starting materials. Discusses disease state, rational for method of drug therapy, biological activities of each compound and preparation. Coverage also includes those generic pharmaceutical compounds not accorded clinical status. A glossary defines biological terms.

Updated every five years, the series represents the optimal compromise between currency and a sufficient body of material for cohesive and comprehensive treatment in a monograph. Provides a quick yet thorough overview of the synthetic routines that have been used to access specific classes of therapeutic agents. Materials are organized by chemical class, and syntheses are taken back to available starting materials. Discusses disease state, rational for method of drug therapy, biological activities of each compound and preparation. Coverage also includes those generic pharmaceutical compounds not accorded clinical status. A glossary defines biological terms.